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Abstract
Background: Traditional drug discovery methods focused on the efficacy of drugs rather than their toxicity.
However, toxicity and/or lack of efficacy are produced when unintended targets are affected in metabolic networks.
Thus, identification of biological targets which can be manipulated to produce the desired effect with minimum
side-effects has become an important and challenging topic. Efficient computational methods are required to identify
the drug targets while incurring minimal side-effects.
Results: In this paper, we propose a graph-based computational damage model that summarizes the impact of
enzymes on compounds in metabolic networks. An efficient method based on Integer Linear Programming formalism
is then developed to identify the optimal enzyme-combination so as to minimize the side-effects. The identified target
enzymes for known successful drugs are then verified by comparing the results with those in the existing literature.
Conclusions: Side-effects reduction plays a crucial role in the study of drug development. A graph-based
computational damage model is proposed and the theoretical analysis states the captured problem is
NP-completeness. The proposed approaches can therefore contribute to the discovery of drug targets. Our
developed software is available at “http://hkumath.hku.hk/~wkc/APBC2018-metabolic-network.zip”.
Keywords: Metabolic network, Integer linear programming, Boolean model
Background
One of the most important biological processes in organ-
ism is metabolism and its dysregulation can contribute to
many human diseases. The manipulation of metabolism
has been extensively studied in the field of metabolic
engineering as many of metabolic process produce com-
modity and specialty chemicals. In particular, production
of industrially valuable products using a microbial host
with recombinant technology becomes one of the most
successful applications of metabolic engineering [1–3].
Metabolic network is used to model the behavior of reac-
tions and chemicals [4]. Authors in [5] have proposed
a new mathematical model for large metabolic network
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and demonstrated that the outcome of network expan-
sion is robust against of single or few reactions. Indeed,
for the analysis of metabolic networks, many studies have
been conducted so as to develop Boolean models. For
example, Smart et al. [6] studied the effect of deletion of
each enzyme in metabolic network of a Boolean model,
and Lemke et al. [7] considered almost the same problem
from the viewpoint of the Boolean aspect. Tamura et al.
[8] developed an integer linear programming method for
Boolean reaction cut (BRC) problem. Furthermore, in [9],
the computational complexity of BRCwas analyzed. In the
Boolean model of metabolic networks, compounds and
reactions can be represented by “OR” and “AND” nodes,
respectively. Li et al. [10] have developed methods for
finding a set of enzymes whose inhibition stops the pro-
duction of the target compound with a minimum elimi-
nation of non-target compounds. Furthermore, Takemoto
et al. [11] and Lee et al. [12] estimated the size distribution
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of the deletion effect of enzymes using a branching pro-
cess. Enumerating all the possible enzyme combination
is infeasible since the number of combination increases
exponentially with the number of enzymes. Lu et al. [13]
developed an integer linear programming method for
designing synthetic metabolic networks by considering
minimum reaction insertion in a Booleanmodel. The pro-
posed method can appropriately solve minimum reaction
insertion in a Boolean network.
In pharmaceutics, the development of drugs mainly
focus on target identification and lead inhibitor identifi-
cation [14]. Furthermore, many researchers have done a
lot of work on the efficacy of drugs regardless of their
side-effects (toxicity). However, toxicity or lack of effi-
cacy may occur when the compounds which are not the
intended targets in the metabolic network. Thus how to
effectively reduce the side-effect of drugs has become an
important and challenging issue. The current works aim
to identify the biological targets (could be enzyme or pro-
tein) for drugs which can be manipulated so as to produce
the desired effect (i.e., curing a disease) with minimum
disruptive side-effects [15, 16]. Drug targets, in partic-
ular enzymes, are chosen to reduce abnormal metabo-
lites by formulating an optimal combination problem in
enzyme combination in metabolic networks [10, 17]. It is
known that the function of enzymes is to catalyze reac-
tions and produces metabolites (compounds) inmetabolic
networks. Human diseases, especially metabolic diseases,
may be directly caused by the accumulation of certain
compounds due to the malfunctions of enzymes. We
denote such compounds as target compounds while the
others as non-target compounds. For example, the mal-
function of enzyme phenylalanine hydroxylase results
in accumulation of the amino acid phenylalanine which
causes the disease phenylketonuria [18]. Therefore, there
is a great need to identify a set of enzymes which are
manipulated by drugs to prevent the buildup of target
compounds with minimal damage. Here damage corre-
sponds to the number of non-target compounds whose
production are forced to stop by the inhibition of that
enzyme (or enzyme set).
Then the problem becomes to identify the optimal
enzyme set whose inhibition eliminates the target com-
pounds and at the same time, incurs minimum damage
based on the given metabolic network and a set of target
compounds. We denote such problem as enzyme combi-
nation identification (ECI). Sridhar et al. [19] developed
a branch-and-bound algorithm to dynamically explore
the search space. Furthermore, two filtering strategies are
proposed to prune the search space to guarantee an opti-
mal solution. However, their algorithm is complicated and
impractical for us to use it. In this paper, we develop
an efficient method based on Integer Linear Program-
ming [20–22] which has a wide application in solving NP-
hard problems. Furthermore, all instances of the original
problem are needed to convert into integer programming
formalization so as to apply the existing free solver called
CPLEX [23].
This paper has two main contributions. First, we formu-
late a new biological problem based on Boolean metabolic
network to identify the drug target with minimum dam-
age. Second, we propose an effective and efficient method,
Integer Linear Programming, (needs O(m + n) variables)
to solve the captured problem and it is easy to implement.
By integrating the human metabolic networks, we have
shown that the proposed approach can accurately identify
the target enzyme set for known drugs in the literature.
Furthermore, experiments have shown that our proposed
method is extremely efficient which can effectively solve
the problem in seconds.
The remainder of the paper is organized as follows.
In “Problem formulation” section, we formulate the cap-
tured problem. “Methods” section presents the algo-
rithm ILP-ECI. In “Results and discussions” section, we
discuss the experimental results and give a theoreti-
cal illustration. Finally, conclusions are given in the last
section.
Problem formulation
A metabolic network can be represented by a directed
graph G = (V ,A) which captures the interaction between
reactions, compound, and enzymes. LetC,R, and E denote
the set of compounds, reactions, and enzymes, respec-
tively. Then VC ,VR and VE denote the set of vertices from
C, R, and E, where VC = {vc1 , vc2 , · · · , vcm} denotes a set
of compound nodes, VR = {vr1 , vr2 , · · · , vrn} represents a
set of reaction nodes and VE = {ve1 , ve2 , · · · , vel } defines
a set of enzyme nodes. The subscript m, n, l denote the
number of compound nodes, reaction nodes and enzyme
nodes, respectively. Here V = VC ∪ VR ∪ VE and VC ∩
VR = {},VC ∩ VE = {},VR ∩ VE = {} hold. Here {}
is the empty set. Let Vs ⊆ VC and Vt ⊆ VC be sets of
source nodes and target nodes, respectively. Source nodes
are those nodes having no incoming edges and they are
the seed compounds. A metabolic network can be defined
as follows:
• For each edge (u, v) ∈ A, either (u ∈ VC) ∧ (v ∈ VR)
or (u ∈ VR) ∧ (v ∈ VC |v ∈ VE) holds and “∧”
represents “AND” function;
• Each source node has no incoming edges;
• For nodes v /∈ Vs and v ∈ VC have at least one
incoming edge.
The main problem Enzyme Combination Identifica-
tion (ECI) in a Boolean network is first described with
a simple example and then followed by its mathematical
formalization.
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A small hypothetical metabolic network is shown in
Fig. 1, where circles, rectangles and triangles represent
compounds, reactions and enzymes, respectively. For
instance, R1 is a reaction, its substrates are C1 and E2 and
its product is C2. Here C5 is the target compound in this
figure which shall be stopped. To stop the production of
C5, reaction R2 must be prevented from taking place. One
of the possible solution is to disrupt one of its catalyzing
enzymes (E1 for instance). Another is to stop the produc-
tion of its reactant compounds (i.e., C2 or C3). If C2 is
stopped, then two possible ways can achieve this effect
(i.e., enzyme E2 or E1 ). It is noted that C2,R2,C7 and R1
forms a cycle, the inhibition of E1 will result in inactivat-
ing reaction R2 which will further makes C2 inproducible.
The other way is inhibiting enzyme E2 which makes R1
inactive and further stop the production of compound C2.
Therefore, the inhibition of enzyme E1 or E2 can result in
stopping the production of the target compound.
We define the Enzyme Combination Identification as
follows.
• Input: A metabolic network and a set of target
compounds T(T ∈ C), C is the set of compounds.
• Output: Find a set of enzymes X(X ∈ E) with
minimum damage, whose inhibition stops the
production of all the compounds in T.
For simplicity, we assume there are no external inputs
to all reactions and all the input compounds related
to reactions are shown in the network. We note that
different compounds and enzymes may have different
levels of importance in the metabolic networks. Here
we assume that all the compounds and enzymes are of
equal importance. We assign binary value (i.e., 0 or 1)
to each node V in the Boolean model. “0” means that
Fig. 1 A graph constructed for a hypothetical metabolic network
the corresponding compound is not producible or the
corresponding reaction is inactive while “1” means that
the corresponding compound is producible and the cor-
responding reaction is active. For the related enzyme
catalyzing the reaction, “1” means that it is active and
“0” means that it is inhibited. Let G be such an assign-
ment (G is a function from V to {0, 1}). For each
node v ∈ V , we write v = 1 (resp., v = 0) if
1 (resp., 0) is assigned to v. Then G can be regarded
as a valid assignment if the following conditions are
satisfied:
(i) For each v ∈ Vs, v = 1.
(ii) For each v /∈ Vs, v = 1 if and only if there is u such
that (u, v) ∈ E and u = 1.
(iii) For each v ∈ Vr , v = 1 if and only if u = 1 holds for
all u such that (u, v) ∈ E.
Condition (ii) implies that compound nodes correspond
to “OR” nodes. Condition (iii) implies that reaction nodes
correspond to “AND” nodes, which means that the output
is forced to 0 when a node is inactivated.
From Fig. 1, we can see that inhibition of E1 results in
the knock out of compoundsC4,C7,C8 andC9 in addition
to the target compound C5. Then we denote the num-
ber of non-target compounds knocked out as the damage,
which is caused by the manipulating the enzyme set in
the metabolic network. It can be seen that the damage of
inhibiting E2 is 2 (i.e., C2 and C4). Compound C7 is still
producible because it can be produced by R3 even after the
inhibition of E2. The damage effect of inhibition of E1 is 4
(i.e., C4,C7,C8 and C9). Both E1 and E2 are potential drug
targets since they can achieve the effect of disrupting the
target compound C5. However, E2 is a better drug target
than E1 owing to the fact that it causes less damage.
Methods
In this section, we introduce integer programming-based
methods for ECI. Integer programming, in particular,
Integer Linear Programming (ILP) is set to minimize (or
maximize) a linear objective function under linear con-
straints with all the variables taking integer values. In the
following, each variable takes including the binary value
(i.e., 0 or 1), representing the Boolean values. We apply
ILP to ECI since ILP is widely used for solving NP-hard
problems.










Qiu et al. BMC Systems Biology 2018, 12(Suppl 1):7 Page 56 of 122
FC5 = 1 (2)
TR1 + FC1 + FC7 + FE2 ≥ 1,
FR1 + TC1 ≥ 1,
FR1 + TC7 ≥ 1,
FR1 + TE2 ≥ 1, (3)
TR2 + FC2 + FC3 + FE1 ≥ 1,
FR2 + TC2 ≥ 1,
FR2 + TC3 ≥ 1,
FR2 + TE1 ≥ 1, (4)
TR3 + FC6 + FE1 ≥ 1,
FR3 + TC6 ≥ 1,
FR3 + TE1 ≥ 1 (5)
TC2 = TR1 (6)
TC4 = TR2 (7)
TC5 = TR2 (8)
FC7 + TR2 + TR3 ≥ 1,
TC7 + FR2 ≥ 1,
TC7 + FR3 ≥ 1 (9)
TC8 = TR3 (10)
TC9 = TR3 (11)
TC1 = 1, TC3 = 1, TC6 = 1 (12)
TX + FX = 1for any X (13)
We denote the above formalization as ILP-ECI. Here all
variables including the value of reaction compound and
enzyme nodes take either 1 or 0. Thus, vri can be either
0 or 1, and vci and vei also take 0 or 1. In this example,
vri = 0 (resp. vri = 1) indicating that the value of reac-
tion i takes 0 is represented by FRi = 1 (resp. TRi = 1)
which implies that the reaction is inactivated (otherwise,
the TRi = 1 implies the reaction is activated). Therefore,
TRi = 0 (equivalent to FRi = 1) means the corresponding
value for true reaction takes 0, which implies the reaction
is inactive. And FRi = 0 (equivalent to TRi = 1) indi-
cates the corresponding value for false reaction takes 0,
which implies the reaction is active. Thus, TRi + FRi = 1
holds for any node i in the network. Similarly, TCi and FCi
are used to represent the values of compound nodes. For
instance, TC2 = 1 means that vc2 = 1 and in other words,
FC2 = 0 since TCi + FCi = 1. Furthermore, vri corre-
sponds to “AND” node which implies that if vei = 0 will
inactivate vri .
The objective function (1) means that the damage
should be minimized. FCi = 1 (or TCi = 0) means that a
compound vci is not producible. Equation (2) means that
the target compound vc5 should be 0 after the 0-1 assign-
ment converges. Equation (3) represents the Boolean rela-
tion vr1 = vc1 ∧ vc7 ∧ ve2 . Note that the Boolean relations
such as “∨” or “∧” cannot be used in ILP formulation,
we need to convert them into linear equations and/or
inequations. Actually, “∨” indicates “AND” function and
“∧”represents “OR” function. Since x1 = x2 ∧ x3 ∧ · · ·∧ xn
can be represented by
(x1∨x2 ∨· · ·∨ xn)∧(x1 ∨ x2)∧(x1 ∨ x3)∧· · ·∧(x1 ∨xn)=1,
the constraint vr1 = vc1 ∧ vc7 ∧ ve2 can be converted into(
vr1∨vc1∨vc7 ∨ ve2
)∧(vr1 ∨vc1)∧(vr1 ∨vc7)∧(vr1∨ve2)=1.
Thus Eq. (3) is obtained. Similarly, Eqs. (4)-(5) represent
the constraints of vr2 and vr3 , respectively.
For a compound node with indegree is 1 which indicates
the node has only one incoming edge, the value of the pre-
decessor is just copied. For instance, since vc2 has only one
predecessor vr1 , vc2 is just copied from vr1 as shown in
Eq. (6). Similarly, vc4 is just copied from vr2 which is shown
in Eq. (7).
However, for a compound node with indegree more
than 1, it is necessary to convert the “∨” relation into lin-
ear equation or inequations. Equation (9) represents the
Boolean relation vc7 = vr2∨vr3 . Since x1 = x2∨x3∨· · ·∨xn
can be represented by
(x1∨x2∨· · ·∨xn)∧(x1 ∨ x2)∧(x1 ∨ x3)∧· · ·∧(x1∨ xn)=1,
vc7 = vr2 ∨ vr3 can be turned into
(
vc7 ∨ vr2 ∨ vr3





. Thus, Eq. (9) can be obtained.
Equation (6) - Eq. (12) represent the constraints of
vc1 , · · · , vc9 respectively. Equation (12) means that vc1 , vc3
and vc6 are 1 since their indegrees is 0.
Equation (13) means that “T” and “F” correspond to
“true (1)” and “false (0)”, respectively, and complement
each other.X in Eq. (13)means any component or reaction
in the metabolic network.
The above formalization can clearly solve ECI and
obtain the correct solution {E2}. Besides, the number of
variables is O(m + n) in the above formalization where
m and n are the number of compounds and reactions,
respectively.
It is noted that solving ILP is NP-complete, however, a
problem that can be formalized as ILP is not always NP-
complete. Thus in the following, we prove that ECI is NP-
complete.
Theorem ECI is NP-complete problem with the maxi-
mum indegree and outdegree being bounded by 2.
Proof Obviously, the problem is in NP, it suffices to
show that it is NP-hardness. The proof is by a polyno-
mial time reduction from minimum edge cover (MEC),
which is a problem for a given graph to find the mini-
mum number of edges so that each node is incident to
at least one of the selected edges. For instance, E1 =
{e2, e3, e6} is one of optimal solutions of MEC for graph
shown in Fig. 2. Let G = (V ,E) be an instance of MEC,
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Fig. 2 An instance of minimum edge cover (MEC)
where V = {v1, v2, · · · , vn} and E = {e1, e2, · · · , em}.
We then construct the corresponding ECI as below.
The metabolite network G = (Vc ∪ Vr ∪ Ve,E) is
given by
Vc = {c1, c2, · · · , cm} ∪ ct , Vr = {r1, r2, · · · , rn} ,




} |j = 1, · · · , n}
It is noted that the minimum damage is determined
uniquely by the inhibition of enzyme set. Furthermore,
our objective is to minimize the “damage” (side-effects).
Then Ve can be regarded as virtual nodes and denoted as
an empty set in this case. The ECI problem can be con-
verted into the problem of identifying the minimum set of
non-target compounds. Thus the graph forMEC shown in
Fig. 2 is converted into ECI shown in Fig. 3. It is clear that
this conversion can be done in polynomial time. Then we
show that MEC for G has a solution of size z if and only
if ECI has a minimum damage of size z. To guarantee that
the target compound ct is stopped (i.e., ct = 0), it implies
that all rj (j = 1, · · · , n) takes the value 0. If G has an edge
cover of size z, then it follows that the minimum number
of ci taking 0 should be z. On the other hand, if the min-
imum damage for ECI is z, then each rj must be 0 so as
to satisfy ct = 0, we have at least predecessor of each rj
must be included in the minimum damage set. Since there
is an edge between ci and rj if and only if vj is incident to
Fig. 3 The polynomial time reduction from minimum edge cover
(MEC) problem to minimum damage identification problem
ei. Thus {ci|ci ∈ minimum damage set} is an edge cover of
size z.
Results and discussions
In this section, we verify the biological validity of our
proposed method by using known drugs. Besides, the
performance of the ILP-ECI algorithm is evaluated by
using the execution time which indicates the total time
taken by the method. For the experimental data, we
extracted the metabolic network information from the
Kyoto Encyclopedia of Genes and Genomes (KEGG)
database [24]. KEGG is database which provides known
drug molecules along the the enzymes they inhibit and
their therapeutic category. Then we use drugs at this
database as our benchmarks and we report two of them
due to the space limitation. And the value in paren-
thesis that starts with letter “C”, “D”, and “E” (e.g.,
E1.13.11.34) is the unique identifier assigned to the cor-
responding compound, drug, and enzyme respectively
in KEGG.
The drug we used in this paper is Benoxaprofen
(D03080) which inhibits arachidonate 5-lipoxygenase
(E1.13.11.34) [25]. This enzyme appears in several
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networks including arachidonic acid metabolism net-
work (hsa00590). In Pharmacology, the inhibition
of 5-lipoxygenase will decrease the biosynthesis of
LTB4 (C02165), cysteinylcontaining leukotrienes LTC4
(C02166), LTD4 (C05951) and LTE4 (C05952) (see, for
instance, Fig. 4) [26]. According to our graph model,
the removal of E1.13.11.34 will eliminate four com-
pounds (LTB4, LTC4, LTD4 and LTE4) in arachidonic
acid metabolism network. Furthermore, these four
compounds play an important role in the mechanisms
of toxic brain damage in acute methanol poisoning
in humans [27]. Thus, we chose them as the target
compounds. Apart from that, inhibiting this enzyme
also eliminates four more compounds (i.e., 5(S)-
HPETE(C05356), 5-HETE(C04805), LTA4(C00909), and
20-OH-LTB4(C04853)) [28]. These compounds can be
regarded as “damage” in our model. Furthermore, when
applying ILP-ECI with LTB4, LTC4, LTD4 and LTE4 as
the target compounds, we find LTA4H (E3.3.2.6) and
LTC4 synthase (E4.4.1.20) as the optimal enzyme set since
the inhibition of these two enzymes eliminates only one
non-target compound namely 20-OH-LTB4 (C04853).
Thus, it is shown that ILP-ECI potentially finds a better
solution in this experiment than the existing drugs since
the same target compounds are eliminated by the existing
drug in addition to other four compounds. Indeed, recent
research validated our model since the anti-inflammatory
effect of the levels of LTA4H [29] and LTC4 [30] has been
observed. The computational time in this experiment
takes only 5.19 s.
Another experiment we conducted is the histi-
dine metabolism network (hsa00340). The enzyme
amine oxidase (E.1.4.3.4) appeared in hsa00340 can
be inhibited by drug (Rasagiline (D02562)). According
to our graph model, the removal of enzyme E.1.4.3.4
will result in eliminating two compounds Methylim-
idazoleacetic acid (C05828) and Methylimidazole
acetaldehyde (C05827). It should be noted that the level of
pros-methylimidazoleacetic acid is closely related to
severity of Parkinson disease in patients [31, 32]. Running
ILP-ECI with Methylimidazoleacetic acid and Methylimi-
dazole acetaldehyde as the target compounds finds amine
oxidase as the optimal enzyme. It takes only 3.26 s to
run ILP-ECI. This experiment verifies that Rasgiline
targets the optimal enzyme. An important advantage of
our Boolean model is its capability of detecting the lack
of substrates where the connectivity-based methods fail
to handle this. Another advantage of this model is its
capability of handling branches and cycles in a pathway
from the source compound to the target compound.
However, there are still have some limitations in this
method. One of the major drawbacks is the assump-
tion that all the compounds and enzymes are of equal
importance. However, different compounds and enzymes
Fig. 4 Subgraph of arachidonic acid metabolism
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may have different levels of importance in the metabolic
networks. Our future work will focus on developing other
models which include the weight of different nodes.
Conclusions
In this paper, we formulate the optimal enzyme combi-
nation identification (ECI) problem as an optimization
problem in Boolean metabolic networks. We have proven
that ECI in the Boolean model is NP-complete and the
target enzyme set is uniquely determined when the tar-
get compounds are given. Furthermore, considering that
an exhaustive search cannot be used to solve ECI when
the network is large, we developed an ILP-based algorithm
for ECI. Considering that the computational time of IP-
based method is exponential to the number of variables,
to improve the scalability of the developed method, it is
vital to reduce the number of variables appearing in IP
formalization. And our proposed IP-based method needs
O(m + n) variables.
The efficiency and effectiveness are validated by the
computational experiments in which datasets were down-
loaded from the KEGG database. The results demonstrate
that the proposed model can accurately identify the tar-
get enzymes for known successful drugs in the literature.
Specifically, ILP-ECI has found a different enzyme set
for the target compounds of Benoxaprofen which indi-
cates that our method has a great potential to be better
than Benoxaprofen. The reason is that the solution of
our algorithm damages only one non-target compound
while Benxaprofen damages 4 non-target compounds
including the compound damaged by ILP-ECI’s solution.
Besides, ILP-ECI has found that the same target enzyme
like Rasagiline when its target compounds are given in
advance. It is to be noted that our problem needs only
O(m + n) variables in the IP formalization. The exper-
iments also show that ILP-ECI can solve the problem
in a short time which confirms the efficiency of our
algorithm.
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